Recent advances in the understanding of endometriosis: the role of inflammatory mediators in disease pathogenesis and treatment

Warren B. Nothnick, Warren Nothnick, Zahraa Alali
F1000Research · 2016 · vol. 5 , pp. 186 · doi:10.12688/f1000research.7504.1 · PMID:26949527 · PMC4760268 · W2286138571
preprint OA: gold CC0 ⤵ 46 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This review discusses the role of inflammatory mediators in endometriosis pathogenesis and treatment, examining past failures of anti-TNF therapies and exploring novel targets like MIF, PGE2, and ER-beta.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

I can’t summarize this paper because the text you provided appears to be unrelated embedded website/JavaScript code rather than the paper’s scientific content (e.g., methods, results, or stated limitations). Without the actual article body, there’s no way to determine what was studied, which population or methods were used, or what key findings and caveats were reported. If you paste the abstract and/or the main sections (or provide the correct article text), I can generate a 3–5 sentence biomedical research summary. This paper is included in the endometriosis corpus based on its title match emphasizing endometriosis inflammatory mediators and treatment, though the provided content does not contain verifiable details.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

In this review, we focus on recent advancements in our understanding of the roles of inflammatory mediators in endometriosis pathophysiology and the potential for improved therapies based upon targeting these pathways. We review the association between endometriosis and inflammation and the initial promise of anti-tumor necrosis factor therapies based upon experimental evidence, and how and why these studies have not translated to the clinic. We then discuss emerging data on the role of inter-relationship among macrophage migration inhibitory factor, prostaglandin E 2, and estrogen receptor-beta, and the potential utility of targeting these factors in endometriosis treatment. In doing so, we highlight the strengths and discuss the current research on identification of novel, anti-inflammatory-based therapy and the necessity to expand experimental endpoints to include clinically relevant measures when assessing the efficacy of potential new therapies for endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (66)

Cited by (47)

Source provenance

europepmc
last seen: 2026-06-11T06:38:44.028908+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:13.485820+00:00
License: CC0 · commercial use OK